Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids

Bader, Johannes; Brigger, Finn; Leroux, Jean-Christophe

doi:10.1016/j.addr.2024.115461

Javascript is disabled or not supported in your browser. JavaScript must be enabled in order for you to use WIKINDX fully. Enable JavaScript through your browser options then try again, otherwise, try using a different browser.

BioAcyl Corp

WIKINDX Resources

Bader, J., Brigger, F., & Leroux, J.-C. (2024). Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Advanced Drug Delivery Reviews, 215, 115461.
Added by: Dr. Enrique Feoli (21/08/2025, 23:53) Last edited by: Dr. Enrique Feoli (21/08/2025, 23:55)

Resource type: Journal Article
DOI: 10.1016/j.addr.2024.115461
ID no. (ISBN etc.): 0169-409X
BibTeX citation key: Bader2024
View all bibliographic details

Categories: BioAcyl Corp
Subcategories: Lipid nanovesicles
Keywords: Clinical trials, Drug loading, Extracellular vesicles, Gene delivery, Lipid nanoparticles, Nucleic acid therapeutics
Creators: Bader, Brigger, Leroux
Collection: Advanced Drug Delivery Reviews

Views: 2/18

Abstract

Extracellular vesicles (EVs) are increasingly investigated for delivering nucleic acid (NA) therapeutics, leveraging their natural role in transporting NA and protein-based cargo in cell-to-cell signaling. Their synthetic counterparts, lipid nanoparticles (LNPs), have been developed over the past decades as NA carriers, culminating in the approval of several marketed formulations such as patisiran/Onpattro® and the mRNA-1273/BNT162 COVID-19 vaccines. The success of LNPs has sparked efforts to develop innovative technologies to target extrahepatic organs, and to deliver novel therapeutic modalities, such as tools for in vivo gene editing. Fueled by the recent advancements in both fields, this review aims to provide a comprehensive overview of the basic characteristics of EV and LNP-based NA delivery systems, from EV biogenesis to structural properties of LNPs. It addresses the primary challenges encountered in utilizing these nanocarriers from a drug formulation and delivery perspective. Additionally, biodistribution profiles, in vitro and in vivo transfection outcomes, as well as their status in clinical trials are compared. Overall, this review provides insights into promising research avenues and potential dead ends for EV and LNP-based NA delivery systems.